Retatrutide half life: how long it stays in your system. | Reddit

Approximately 6 days. The phase 1b multiple-ascending-dose trial in people with type 2 diabetes, published in The Lancet in 2022, reported that retatrutide’s pharmacokinetics were dose proportional and that its half-life was approximately 6 days. That single sentence is the anchor for everything else on this page, because half-life is the number that sets the dosing interval, the time to steady state, and the washout period.

Half-life means the time it takes for the concentration of a drug in plasma to fall by half. It does not mean the time the drug works for, and it does not mean the time until effects appear. Those are separate questions with separate published answers, covered in our how long retatrutide takes to work article.

From the early-phase clinical program, which is where pharmacokinetics get established for any drug. The phase 1b trial randomised people with type 2 diabetes to once-weekly subcutaneous retatrutide or placebo for 12 weeks across five ascending dose cohorts: 0.5 mg, 1.5 mg, 3 mg, a 3/6 mg escalation, and a 3/6/9/12 mg escalation. Alongside the half-life finding, it reported a placebo-adjusted bodyweight reduction of up to 8.96 kg in the highest escalation group at 12 weeks.

The discovery-to-clinic report in Cell Metabolism, also 2022, adds the single-dose picture: in the phase 1 single-ascending-dose study, the pharmacokinetic profile supported once-weekly dosing, and a reduction in body weight persisted up to day 43 after a single dose.

The three sit within about two days of each other, and all three support once-weekly injection. A 2018 review in Clinical Pharmacokinetics reports that at a dose of 0.5 or 1 mg, subcutaneous semaglutide has a half-life of 7 days, and a 2019 ascending-dose study in the same journal found the half-life of semaglutide was approximately 1 week in all groups. For tirzepatide, a 2024 population pharmacokinetic analysis reported a half-life of about 5 days with sustained exposure under once-weekly subcutaneous dosing.

The practical difference between the three compounds is not the day of half-life. It is regulatory status: two have approved products and one is investigational. For the efficacy side of that comparison, see retatrutide vs tirzepatide.

Because the half-life makes a weekly interval workable. A drug with a half-life of approximately 6 days loses about half its concentration between weekly injections, which keeps exposure within a band a weekly schedule can maintain. The Cell Metabolism report states the conclusion directly: the pharmacokinetic profile supported once-weekly dosing.

The single-dose data point is worth restating, because it is the cleanest published illustration of how long-acting this molecule is: after one injection in the phase 1 single-ascending-dose study, a reduction in body weight persisted up to day 43.

The published trials did not report a washout dataset, so the honest answer is arithmetic from the published half-life, and it should be read as arithmetic rather than as a measured result. At a half-life of approximately 6 days, a single dose falls to about 45% of its level a week after injection, and the standard pharmacology rule in StatPearls holds that after 4 to 5 half-lives a drug’s plasma concentration typically falls below a clinically relevant level and is considered effectively eliminated. For retatrutide that is roughly 24 to 30 days.

With repeated weekly dosing, each new injection lands on top of what remains of the previous ones, and levels climb until input and elimination balance. Per StatPearls, a drug achieves steady-state concentration after approximately 4 to 5 half-lives of regular dosing, without further accumulation. At approximately 6 days per half-life, retatrutide’s arithmetic answer is 24 to 30 days, which is roughly the fourth or fifth weekly injection.

In practice the trials complicate that clean picture, because they escalated doses on the way up: the phase 2 diabetes trial ran separate slow-escalation and fast-escalation arms to the same 8 mg target. Each escalation step resets the climb toward a new, higher steady state. The full week-by-week picture across the program is in our retatrutide timeline article.

There is no official answer, and it is worth being precise about why. Approved drugs carry prescribing information, and missed-dose instructions live there. Retatrutide has no approved product, so no prescribing information exists, and the published trial abstracts describe fixed once-weekly schedules rather than missed-dose substudies. Anyone stating a definite missed-dose rule for retatrutide is not quoting a published source.

What the half-life allows is plain decay arithmetic. Thirteen days after an injection, a week overdue, roughly 22% of that dose remains. After two missed weeks, 20 days out, the figure is near 10%. The arithmetic describes blood levels only. It says nothing about what anyone should do, which is a clinical question that has no approved answer for an investigational compound.

By the same 4-to-5-half-lives rule, plasma levels fall below a clinically relevant concentration roughly 24 to 30 days after the final injection. About a month is the defensible one-line answer, with the caveat that it is derived from the published half-life rather than from a dedicated washout study.

Drug level and drug effect are not the same clock. The single-dose data showed a bodyweight reduction persisting to day 43, past the point where most of that dose had been eliminated. What happens to weight after discontinuation is a separate question the published retatrutide abstracts do not answer, and it is one of the honest gaps in the record.

No. Concentration and effect run on different schedules, and the trials deliberately started low: initial doses in the phase 2 obesity trial were 2 mg or 4 mg against final targets as high as 12 mg. Levels build toward steady state over the first 4 to 5 weeks while the assigned dose is still escalating, which is why the early weeks of the published trials ran quiet relative to the headline numbers.

A widely shared dose-ladder video claims the trial doses were 2, 4, 6, 9 and 12 mg, spaced at 4-week intervals. Treat that as a creator claim, not a trial fact: it does not match any dose list in the published abstracts. The phase 1b trial escalated through 3, 6, 9 and 12 mg; the phase 2 obesity trial assigned 1 to 12 mg targets with 2 mg or 4 mg starting doses; the phase 3 TRANSCEND-T2D-1 trial ran 4, 9 and 12 mg arms. The 4-week-interval detail is likewise not stated in these abstracts, which describe slow and fast escalation arms without publishing the step calendar.

The same video floats microdosing, splitting a weekly dose into smaller, more frequent injections to flatten peaks, and pairs it with a receptor desensitisation concern the creator plainly labels a personal theory. No published retatrutide trial tested a split-dose schedule, so there is no human evidence on either side of that idea.

A fair amount, and saying so plainly beats padding the gap with confident numbers. The abstracts establish the half-life, dose proportionality and the once-weekly rationale. They do not carry the full pharmacokinetic workup an approved drug publishes in its label.

The 6-day figure was measured with a defined pharmaceutical product of known identity, concentration and sterility, inside monitored trials. A vial from a research-chemical site carries none of those guarantees, so no pharmacokinetic number on this page can be assumed to describe it. That is not a technicality: half-life arithmetic is only as good as knowing what and how much was injected.

If the underlying goal is metabolic and weight management support, there are therapies a licensed clinician can prescribe today and a licensed US pharmacy can prepare today. Semaglutide and tirzepatide both have approved products behind them and an established prescribing route, and a clinician decides whether either is appropriate for your history.

Every dose PepScribe dispenses is compounded in the USA by licensed 503A pharmacies. No hidden overseas supply chain. The online visit is free, and you pay only if a clinician prescribes.